

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)

[0001130166](#)

Name of Issuer

[Cyclacel Pharmaceuticals, Inc.](#)

Jurisdiction of Incorporation/Organization

[DELAWARE](#)

Year of Incorporation/Organization

Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

Previous
Names

None

[XYCYTE THERAPIES INC](#)

[MolecuRx, Inc.](#)

[CDR Therapeutics, Inc.](#)

[Xcyte Therapies, Inc](#)

Entity Type

Corporation

Limited Partnership

Limited Liability Company

General Partnership

Business Trust

Other (Specify)

2. Principal Place of Business and Contact Information

Name of Issuer

[Cyclacel Pharmaceuticals, Inc.](#)

Street Address 1

[200 CONNELL DRIVE, SUITE 1500](#)

City

[BERKELEY HEIGHTS](#)

State/Province/Country

[NEW JERSEY](#)

Street Address 2

ZIP/PostalCode

[07922](#)

Phone Number of Issuer

[908-517-7330](#)

3. Related Persons

Last Name

[Lazar](#)

First Name

[David](#)

Middle Name

Street Address 1

[c/o Cyclacel Pharmaceuticals, Inc.](#)

Street Address 2

[200 Connell Drive, Suite 1500](#)

City

[Berkeley Heights](#)

State/Province/Country

[NEW JERSEY](#)

ZIP/PostalCode

[07922](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name

[Natan](#)

First Name

[David](#)

Middle Name

Street Address 1

[c/o Cyclacel Pharmaceuticals, Inc.](#)

Street Address 2

[200 Connell Drive, Suite 1500](#)

City

[Berkeley Heights](#)

State/Province/Country

[NEW JERSEY](#)

ZIP/PostalCode

[07922](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name

[Ben-Tzvi](#)

First Name

[Avraham](#)

Middle Name

Street Address 1

[c/o Cyclacel Pharmaceuticals, Inc.](#)

Street Address 2

[200 Connell Drive, Suite 1500](#)

City

[Berkeley Heights](#)

State/Province/Country

[NEW JERSEY](#)

ZIP/PostalCode

[07922](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name **Rombotis** First Name **Spiro** Middle Name
Street Address 1 **c/o Cyclacel Pharmaceuticals, Inc.** Street Address 2 **200 Connell Drive, Suite 1500**
City **Berkeley Heights** State/Province/Country **NEW JERSEY** ZIP/PostalCode **07922**
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name **McBarron** First Name **Paul** Middle Name
Street Address 1 **c/o Cyclacel Pharmaceuticals, Inc.** Street Address 2 **200 Connell Drive, Suite 1500**
City **Berkeley Heights** State/Province/Country **NEW JERSEY** ZIP/PostalCode **07922**
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name **Barker** First Name **Samuel** Middle Name
Street Address 1 **c/o Cyclacel Pharmaceuticals, Inc.** Street Address 2 **200 Connell Drive, Suite 1500**
City **Berkeley Heights** State/Province/Country **NEW JERSEY** ZIP/PostalCode **07922**
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

- | | | |
|---|---|--|
| <input type="checkbox"/> Agriculture | <input type="checkbox"/> Health Care | <input type="checkbox"/> Retailing |
| <input type="checkbox"/> Banking & Financial Services | <input checked="" type="checkbox"/> Biotechnology | <input type="checkbox"/> Restaurants |
| <input type="checkbox"/> Commercial Banking | <input type="checkbox"/> Health Insurance | <input type="checkbox"/> Technology |
| <input type="checkbox"/> Insurance | <input type="checkbox"/> Hospitals & Physicians | <input type="checkbox"/> Computers |
| <input type="checkbox"/> Investing | <input type="checkbox"/> Pharmaceuticals | <input type="checkbox"/> Telecommunications |
| <input type="checkbox"/> Investment Banking | <input type="checkbox"/> Other Health Care | <input type="checkbox"/> Other Technology |
| <input type="checkbox"/> Pooled Investment Fund | <input type="checkbox"/> Manufacturing | <input type="checkbox"/> Travel |
| Is the issuer registered as an investment company under the Investment Company Act of 1940? | <input type="checkbox"/> Real Estate | <input type="checkbox"/> Airlines & Airports |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | <input type="checkbox"/> Commercial | <input type="checkbox"/> Lodging & Conventions |
| <input type="checkbox"/> Other Banking & Financial Services | <input type="checkbox"/> Construction | <input type="checkbox"/> Tourism & Travel Services |
| <input type="checkbox"/> Business Services | <input type="checkbox"/> REITS & Finance | <input type="checkbox"/> Other Travel |
| <input type="checkbox"/> Energy | <input type="checkbox"/> Residential | <input type="checkbox"/> Other |
| <input type="checkbox"/> Coal Mining | <input type="checkbox"/> Other Real Estate | |
| <input type="checkbox"/> Electric Utilities | | |
| <input type="checkbox"/> Energy Conservation | | |
| <input type="checkbox"/> Environmental Services | | |
| <input type="checkbox"/> Oil & Gas | | |
| <input type="checkbox"/> Other Energy | | |

5. Issuer Size

- | | | |
|---|----|---|
| Revenue Range | OR | Aggregate Net Asset Value Range |
| <input type="checkbox"/> No Revenues | | <input type="checkbox"/> No Aggregate Net Asset Value |
| <input type="checkbox"/> \$1 - \$1,000,000 | | <input type="checkbox"/> \$1 - \$5,000,000 |
| <input type="checkbox"/> \$1,000,001 - \$5,000,000 | | <input type="checkbox"/> \$5,000,001 - \$25,000,000 |
| <input type="checkbox"/> \$5,000,001 - \$25,000,000 | | <input type="checkbox"/> \$25,000,001 - \$50,000,000 |
| <input type="checkbox"/> \$25,000,001 - | | <input type="checkbox"/> \$50,000,001 - \$100,000,000 |

- \$100,000,000
 Over \$100,000,000
 Decline to Disclose
 Not Applicable

- Over \$100,000,000
 Decline to Disclose
 Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- Rule 504(b)(1) (not (i), (ii) or (iii))
 Rule 504 (b)(1)(i)
 Rule 504 (b)(1)(ii)
 Rule 504 (b)(1)(iii)
 Rule 506(b)
 Rule 506(c)
 Securities Act Section 4(a)(5)
- Investment Company Act Section 3(c)
 Section 3(c)(1)
 Section 3(c)(2)
 Section 3(c)(3)
 Section 3(c)(4)
 Section 3(c)(5)
 Section 3(c)(6)
 Section 3(c)(7)
- Section 3(c)(9)
 Section 3(c)(10)
 Section 3(c)(11)
 Section 3(c)(12)
 Section 3(c)(13)
 Section 3(c)(14)

7. Type of Filing

- New Notice Date of First Sale First Sale Yet to Occur
 Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- Equity
 Debt
 Option, Warrant or Other Right to Acquire Another Security
 Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- Pooled Investment Fund Interests
 Tenant-in-Common Securities
 Mineral Property Securities
 Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient (Associated) Broker or Dealer None
 Street Address 1
 City
 State(s) of Solicitation (select all that apply) All States Foreign/non-US
 Check "All States" or check individual States

Recipient CRD Number None
 (Associated) Broker or Dealer CRD Number None
 Street Address 2
 State/Province/Country
 ZIP/Postal Code

13. Offering and Sales Amounts

Total Offering Amount \$25,000,000 USD or Indefinite
 Total Amount Sold \$0 USD
 Total Remaining to be Sold \$25,000,000 USD or Indefinite

Clarification of Response (if Necessary):

On February 5, 2025 the Company entered into a securities purchase agreement with Helena Special Opportunities 1 Ltd. Please refer to the disclosure contained in the Company's Current Report on Form 8-K, filed with the SEC on February 6, 2025.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Please refer to the disclosure contained in Item 1.01 of the Company's Current Report on Form 8-K, filed with the SEC on February 6, 2025.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Please refer to the disclosure contained in Item 1.01 of the Company's Current Report on Form 8-K, filed with the SEC on February 6, 2025.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking **SUBMIT** below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer | Signature | Name of Signer | Title | Date |
|--------------------------------|-----------------|----------------|---------------------------------|------------|
| Cyclacel Pharmaceuticals, Inc. | /s/ David Lazar | David Lazar | Interim Chief Executive Officer | 2025-02-14 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.